DobbieJ.W.Pathology of the peritoneum. In: BengmarkS., ed. The peritoneum and peritoneal access.Butterworth & CoLondon, U.K.1989: 42–52.
2.
DobbieJ.W.Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.Perit Dial Int1992; 12: 14–27.
3.
LiberekT., TopleyN., MistryC.D.Cell function and viability in glucose polymer peritoneal dialysis fluids.Perit Dial Int, Vo1 13, No 2.
4.
JonjicN., PeriG., BernasconiS.Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells.J Exp Med1992; 176: 1165–1174.
5.
LanfranconeL., BoraschiD., GhiaraP.Human peritoneal mesothelial cells produce many cytokines (granulocyte colony -stimulating factor [CSF], granulo cyte-monocyte-CSF, macrophage-CSF, interleukin 1 [IL-l], and IL-6) and are activated and stimulated to grow by IL-l.Blood1992; 11: 2835–2842.
6.
TopleyN., JörresA., LuttmanW.Human peritoneal mesothelial cells synthesize interleukin 6: Induction by IL-lβ and TNFα.Kidney Int1993; 43: 226–233.
TopleyN., AlobaidiH.M.M., DaviesM.The effect of dialysate on peritoneal phagocyte oxidative metabolism.Kidney Int1988; 34: 404–11.
9.
TopleyN., MackenzieR., PetersenM.M.In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid.Nephrol Dial Transplant1991; 6: 574–81.
10.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
11.
IngB.L., GuptaZ.M., NawabF-Q.Suppression of neutrophil superoxide production by conventional peritoneal dialysis solution.Int J Artif Organs1988; 11: 351–4.
12.
van BronswijkH., VerbrughH.A., HeeziusH.C.J.M.Dialysis fluid and local host resistance in patients on continuous ambulatory peritoneal dialysis.Eur J Clin Infect Dis1988; 7: 368–73.
13.
SchambyeH.T., PedersenF.B., WangP.Cytotoxicity of continuous ambulatory peritoneal dialysis (CAPD) solutions. A biocompatibility study involving human polymorphonuclear granulocytes rather than laboratory animals.North Scand Cell Toxicol Congress1992; 20: 275–9.
14.
JörresA., JörresD., TopleyN.Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions.Nephrol Dial Transplant1991; 6: 495–501.
15.
JörresA., JörresD., GahlG.M.Leukotriene B4 and tumor necrosis factor from leukocytes: Effect of peritoneal dialysate.Nephron1991; 58: 276–82.
16.
JörresA., RichterD., HamH.Cytokine release from peripheral and peritoneal phagocytes: Effect of CAPD dialysate.Kidney Int1990; 37: 329.
17.
VerbrughH.A., KeaneW.F., HoidelJ.F.Peritoneal macrophages and opsonins: Antibacterial defense in patients undergoing chronic peritoneal dialysis.J InfectDis1983; 147: 1018–29.
18.
McGregorS.J., BrockJ.H., BriggsJ.D.Bactericidal activity of peritoneal macrophages from continuous ambulatory peritoneal dialysis patients.Nephrol Dial Transplant1987; 2: 104–8.
19.
AlobaidiH.M., ColesG.A., DaviesM.Host defense in continuous ambulatory peritoneal dialysis: The effect of the dialysate on phagocyte function.Nephrol Dial Transplant1986; 1: 16–21.
20.
JörresA., GahlG.M., LudatK.In vitro biocompatibility testing of a new bicarbonate-buffered dialysis fluid for CAPD.Perit Dial Int1992; 12(Suppl 2): S26.
21.
AndreA., EgleB., DobosG.J.Comparison of lactate and bicarbonate buffered peritoneal dialysis (PD) fluids: Effect on human peritoneal macrophage (PMO).Perit Dial Int1993; 13 (Suppll), S24.
22.
ManghallN.A., McGregorS.J., BrockJ.H.Expression of transferrin receptors by monocytes and peritoneal macrophages from renal failure patients treated by continuous ambulatory peritoneal dialysis (CAPD).Eur J Clin Invest1991; 21: 592–6.
23.
DaviesS.J., SuassunaJ., OggC.S.Activation of immunocompetent cells in the peritoneum of patients treated with CAPD.Kidney Int1989; 36: 661–8.
24.
LewisS.L., NorrisP.J., HolmesC.J.Phenotypic characterization of monocytes and macrophages from CAPD patients.Trans Am Soc Artif Intern Organs1990; XXXVl: M575–7.
25.
KraneS.M., GoldingM.D.Potential role for interleukin1 in fibrosis associated with chronic ambulatory peritoneal dialysis.Blood Purif1988; 6: 173–7.
26.
BreborowiczA.Free radicals in peritoneal dialysis: Agents of damage?Perit Dial Int1992; 12: 194–8.
27.
BosH.J., MeyerF., de VeldJ.C.Peritoneal dialysis fluid induces change of mononuclear phagocyte proportions.Kidney Int1989; 36: 20–6.
28.
VachulaM., AonoF., KubeyW.Effect of peritoneal dialysis fluid on mononuclear cell surface receptor expression.J Am Soc Nephrol1991; 2: 368.
29.
van BronswijkH., VerbrughH.A., BosH.J.Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro.Perit Dial Int1989; 9: 197–202.
de FijterC.W.H., VerbrughH.A., PetersE.D.J.An other reason to restrict the use of hypertonic, glucosebased peritoneal dialysis fluid: Its impact on peritoneal macrophage function in vivo. In: KhannaR., NolphK.D., ProwantB., eds. Advances in continuous ambulatory peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, Inc.1991: 150–3.
32.
LiberekT., TopleyN., JörresA.Peritoneal dialysis fluid inhibition of phagocyte function: Effects of osmolality and glucose concentration.J Am Soc Nephrol1993; 3(8): 1508–1515.
33.
BreborowiczA., RodelaH., OreopoulosD.G.Toxicity of osmotic solutes on human mesothelial cells in vitro.Kidney Int1992; 41: 1280–5.
34.
VlassaraH.Advanced nonenzymatic tissue glycosylation: Cell-mediated interactions replicated in the complications associated with diabetes and aging.Blood Purif1990; 8: 223–32.
35.
de FijterC.W.H., VerbrughH.A., OeP.L.The effect of glycerol-containing peritoneal dialysis fluid on peritoneal macrophage function in vivo. In: KhannaR., NolphK.D., ProwantB., eds. Advances in continuous ambulatory peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, Inc.1991: 154–7.
36.
JörresA., GahlG.M., MullerC.In vitro bio-compat-ibility testing of a new glucose polymer dialysis fluid for CAPD. Abstracts of XXIXth congress of the European Dialysis and Transplant Association 1992: 154.
37.
de FijterC.W.H., OeP.L., VerbrughH.A.Glucose. polymers as osmotic agents in CAPD fluids: A more favorable effect on peritoneal macrophage (PMO) function than glucose-based solutions.Kidney Int1991; 40(5): 978.
38.
BrunoM., BagnisC., MarangellaM.CAPD with an amino acid dialysis solution: A long-term cross-over study.Kidney Int1989; 35: 1189–94.
39.
PedersenF.D., DragsholtC., LaierE.Alternate use of amino acid and glucose solutions in CAPD.Perit Dial Bull1985; 5: 215–8.
40.
YoungG., DibbleJ.B., TaylorA.E.A longitudinal study of the effects of amino acid-based CAPD fluid on amino acid retention and protein losses.Nephrol Dial Transplant1989; 4: 900–5.
41.
HolmesC.J., KubeyW., AonoF.In vitro effect of an amino acid-based peritoneal dialysis fluid on human leukocyte function and receptor expression.J Am Soc Nephrol1992; 3(3): 412
42.
BreborowiczA., WitoskiJ., KrapowskiJ.In vitro cytotoxicity of amino acids to human mesothelial cells.Perit Dial Int1991; 11(Suppl 1): Abstract 30.
43.
BreborowiczA., BolaskasE., OreopoulosG.A new approach in the study of dialysis fluid toxicity on the peritoneal membrane.Perit Dial Int1991; 11: (Suppl 1):Abstract 29.
44.
BreborowiczA., BalaskasE., OreopoulosG.Co-culture of peritoneal dialysate cells with mesothelial cells and fibroblasts.Perit Dial Int1991; 11(Suppl 1): Abstract 31.
45.
BarrR.M., SymondsP.A., AkpanA.S.Culture of human dermal fibroblasts in collagen gels: Modulation ofinterleukin-l induced prostaglandin E2 synthesis by an extracellular matrix.Exp Cell Res1992; 198: 321327.
46.
TrigliaD., Sherarel BruaS., YonanC.Cytotoxicity testing using neutral red and MTr assays on a three dimensional human skin substrate.Toxic in vitro1991; 5: 573–8.
